276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

S.M. Tolaney, E. de Azambuja, L.A. Emens, S. Loi, W. Pan, Jingdong Huang, Shi-meng Sun, C. Lai, P. Schmid